Currently out of the existing stock ratings of Kevin Degeeter, 106 are a BUY (93.81%), 6 are a HOLD (5.31%), 1 are a SELL (0.88%).

Kevin Degeeter

Work Performance Price Targets & Ratings Chart

Analyst Kevin Degeeter, carries an average stock price target met ratio of 43.55% that have a potential upside of 45.48% achieved within 133 days. Previously, Kevin Degeeter worked at OPPENHEIMER.

Kevin Degeeter’s has documented 205 price targets and ratings displayed on 30 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ANTX, AN2 Therapeutics at 13-Sep-2023.

Wall Street Analyst Kevin Degeeter

Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for NVTA (INVITAE CORP) at 1/12/2021. The price target of $51 was fulfilled within 1 day with a profit of $3.41 (7.17%) receiving and performance score of 71.65.

Average potential price target upside

of $32.06 (35.54%) on EXAS (EXACT SCIENCES).
of $26.26 (54.07%) on FLGT (FULGENT GENETICS).
of $22.74 (211.91%) on BNGO (BIONANO GENOMICS).

BNGO Bionano Genomics CYCC Cyclacel Pharmaceuticals DMTK DermTech EXAS EXACT Sciences FLGT Fulgent Genetics HGEN Humanigen INFI Infinity Pharmaceuticals IONS Ionis Pharmaceuticals MTEM Molecular Templates NVAX Novavax NVCR Novocure Ltd NVTA Invitae Corp OPK Opko Health ORIC Oric Pharmaceuticals ORTX Orchard Therapeutics PLC PRTG Portage Biotech PSNL Personalis PTE Polarityte SNSE Sensei Biotherapeutics SPRO Spero Therapeutics VCEL Vericel Corp Ord ANTX AN2 Therapeutics CBIO Catalyst Biosciences CDTX Cidara Therapeutics IDYA Ideaya Biosciences KIN Kindred Biosciences MBRX Moleculin Biotech MDXH MDxHealth SA ADR SERA Sera Prognostics GHDX Genomic Health

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Mark Massaro (BTIG)